APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drugs for the Treatment of Refractory Gout

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for the Treatment of Refractory Gout Market Outlook and Growth Opportunities 2026

Report ID 173986530427 December 2025193 pages

Choose your research edition.

Industry ResearchDrugs for the Treatment of Refractory Gout Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for the Treatment of Refractory Gout Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Drugs for the Treatment of Refractory Gout Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for the Treatment of Refractory Gout Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for the Treatment of Refractory Gout Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Drugs for the Treatment of Refractory Gout market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for the Treatment of Refractory Gout is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for the Treatment of Refractory Gout market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for the Treatment of Refractory Gout market include Zhuhai Livzon Biotechnology, Sobi, Qilu Pharmaceutical, Roche, Bio-Thera Solutions, Sandoz, Pfizer, Novartis and Kiniksa Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Drugs for the Treatment of Refractory Gout market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for the Treatment of Refractory Gout and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for the Treatment of Refractory Gout sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Drugs for the Treatment of Refractory Gout market size, projected growth trends, production technologies, key applications, and end-use industries.

Drugs for the Treatment of Refractory Gout Segment by Company

Zhuhai Livzon Biotechnology

Sobi

Qilu Pharmaceutical

Roche

Bio-Thera Solutions

Sandoz

Pfizer

Novartis

Kiniksa Pharmaceuticals

Horizo​​n Therapeutics

Hanwha Chemical

Fresenius Kabi

Biogen

Amgen

Drugs for the Treatment of Refractory Gout Segment by Type

Tumor Necrosis Factor Inhibitors

PEGylated Recombinant Uricase

Interleukin Inhibitors

Other

Drugs for the Treatment of Refractory Gout Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Drugs for the Treatment of Refractory Gout Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drugs for the Treatment of Refractory Gout status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Drugs for the Treatment of Refractory Gout market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for the Treatment of Refractory Gout significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for the Treatment of Refractory Gout competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for the Treatment of Refractory Gout market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for the Treatment of Refractory Gout and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for the Treatment of Refractory Gout.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Drugs for the Treatment of Refractory Gout market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for the Treatment of Refractory Gout industry.

Chapter 3: Detailed analysis of Drugs for the Treatment of Refractory Gout manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Drugs for the Treatment of Refractory Gout in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Drugs for the Treatment of Refractory Gout in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for the Treatment of Refractory Gout Industry Trends Table 2. Drugs for the Treatment of Refractory Gout Industry Drivers Table 3. Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges Table 4. Drugs for the Treatment of Refractory Gout Industry Restraints Table 5. Global Drugs for the Treatment of Refractory Gout Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for the Treatment of Refractory Gout Revenue Share by Company (2021-2026) Table 7. Global Drugs for the Treatment of Refractory Gout Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Company (2021-2026) Table 9. Global Drugs for the Treatment of Refractory Gout Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Drugs for the Treatment of Refractory Gout Company Ranking, (2024-2026) & (USD Million) Table 11. Global Drugs for the Treatment of Refractory Gout Key Company Manufacturing Base & Headquarters Table 12. Global Drugs for the Treatment of Refractory Gout Company, Product Type & Application Table 13. Global Drugs for the Treatment of Refractory Gout Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Drugs for the Treatment of Refractory Gout by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tumor Necrosis Factor Inhibitors Table 18. Significant Companies of PEGylated Recombinant Uricase Table 19. Significant Companies of Interleukin Inhibitors Table 20. Significant Companies of Other Table 21. Global Drugs for the Treatment of Refractory Gout Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Drugs for the Treatment of Refractory Gout Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Drugs for the Treatment of Refractory Gout Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Type (2021-2026) Table 25. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Type (2027-2032) Table 26. Global Drugs for the Treatment of Refractory Gout Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drugs for the Treatment of Refractory Gout Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Drugs for the Treatment of Refractory Gout Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Type (2021-2026) Table 30. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital and Clinic Table 32. Significant Companies of Retail Pharmacies Table 33. Significant Companies of Other Table 34. Global Drugs for the Treatment of Refractory Gout Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Drugs for the Treatment of Refractory Gout Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Drugs for the Treatment of Refractory Gout Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Application (2021-2026) Table 38. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Application (2027-2032) Table 39. Global Drugs for the Treatment of Refractory Gout Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Drugs for the Treatment of Refractory Gout Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Drugs for the Treatment of Refractory Gout Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Application (2021-2026) Table 43. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Application (2027-2032) Table 44. Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2026) & (K Units) Table 46. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2021-2026) Table 47. Global Drugs for the Treatment of Refractory Gout Sales by Region (2027-2032) & (K Units) Table 48. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region (2027-2032) Table 49. Global Drugs for the Treatment of Refractory Gout Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Drugs for the Treatment of Refractory Gout Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Region (2021-2026) Table 52. Global Drugs for the Treatment of Refractory Gout Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Region (2027-2032) Table 54. Global Drugs for the Treatment of Refractory Gout Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Drugs for the Treatment of Refractory Gout Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Drugs for the Treatment of Refractory Gout Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Drugs for the Treatment of Refractory Gout Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026) & (K Units) Table 59. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2021-2026) Table 60. Global Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032) & (K Units) Table 61. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Country (2027-2032) Table 62. Global Drugs for the Treatment of Refractory Gout Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Drugs for the Treatment of Refractory Gout Sales Value Market Share by Country (2021-2026) Table 64. Global Drugs for the Treatment of Refractory Gout Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Drugs for the Treatment of Refractory Gout Sales Value Market Share by Country (2027-2032) Table 66. Zhuhai Livzon Biotechnology Company Information Table 67. Zhuhai Livzon Biotechnology Business Overview Table 68. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio Table 70. Zhuhai Livzon Biotechnology Recent Development Table 71. Sobi Company Information Table 72. Sobi Business Overview Table 73. Sobi Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Sobi Drugs for the Treatment of Refractory Gout Product Portfolio Table 75. Sobi Recent Development Table 76. Qilu Pharmaceutical Company Information Table 77. Qilu Pharmaceutical Business Overview Table 78. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio Table 80. Qilu Pharmaceutical Recent Development Table 81. Roche Company Information Table 82. Roche Business Overview Table 83. Roche Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Roche Drugs for the Treatment of Refractory Gout Product Portfolio Table 85. Roche Recent Development Table 86. Bio-Thera Solutions Company Information Table 87. Bio-Thera Solutions Business Overview Table 88. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio Table 90. Bio-Thera Solutions Recent Development Table 91. Sandoz Company Information Table 92. Sandoz Business Overview Table 93. Sandoz Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio Table 95. Sandoz Recent Development Table 96. Pfizer Company Information Table 97. Pfizer Business Overview Table 98. Pfizer Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio Table 100. Pfizer Recent Development Table 101. Novartis Company Information Table 102. Novartis Business Overview Table 103. Novartis Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Novartis Drugs for the Treatment of Refractory Gout Product Portfolio Table 105. Novartis Recent Development Table 106. Kiniksa Pharmaceuticals Company Information Table 107. Kiniksa Pharmaceuticals Business Overview Table 108. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio Table 110. Kiniksa Pharmaceuticals Recent Development Table 111. Horizo​​n Therapeutics Company Information Table 112. Horizo​​n Therapeutics Business Overview Table 113. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio Table 115. Horizo​​n Therapeutics Recent Development Table 116. Hanwha Chemical Company Information Table 117. Hanwha Chemical Business Overview Table 118. Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio Table 120. Hanwha Chemical Recent Development Table 121. Fresenius Kabi Company Information Table 122. Fresenius Kabi Business Overview Table 123. Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio Table 125. Fresenius Kabi Recent Development Table 126. Biogen Company Information Table 127. Biogen Business Overview Table 128. Biogen Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Biogen Drugs for the Treatment of Refractory Gout Product Portfolio Table 130. Biogen Recent Development Table 131. Amgen Company Information Table 132. Amgen Business Overview Table 133. Amgen Drugs for the Treatment of Refractory Gout Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Amgen Drugs for the Treatment of Refractory Gout Product Portfolio Table 135. Amgen Recent Development Table 136. Key Raw Materials Table 137. Raw Materials Key Suppliers Table 138. Drugs for the Treatment of Refractory Gout Distributors List Table 139. Drugs for the Treatment of Refractory Gout Customers List Table 140. Research Programs/Design for This Report Table 141. Authors List of This Report Table 142. Secondary Sources Table 143. Primary Sources List of Figures Figure 1. Drugs for the Treatment of Refractory Gout Product Image Figure 2. Global Drugs for the Treatment of Refractory Gout Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for the Treatment of Refractory Gout Sales Value (2021-2032) & (US$ Million) Figure 4. Global Drugs for the Treatment of Refractory Gout Sales (2021-2032) & (K Units) Figure 5. Global Drugs for the Treatment of Refractory Gout Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Drugs for the Treatment of Refractory Gout Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tumor Necrosis Factor Inhibitors Image Figure 10. PEGylated Recombinant Uricase Image Figure 11. Interleukin Inhibitors Image Figure 12. Other Image Figure 13. Global Drugs for the Treatment of Refractory Gout Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Drugs for the Treatment of Refractory Gout Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Type (2021-2032) Figure 16. Global Drugs for the Treatment of Refractory Gout Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs for the Treatment of Refractory Gout Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Type (2021-2032) Figure 19. Hospital and Clinic Image Figure 20. Retail Pharmacies Image Figure 21. Other Image Figure 22. Global Drugs for the Treatment of Refractory Gout Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Drugs for the Treatment of Refractory Gout Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Application (2021-2032) Figure 25. Global Drugs for the Treatment of Refractory Gout Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Drugs for the Treatment of Refractory Gout Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Application (2021-2032) Figure 28. Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Drugs for the Treatment of Refractory Gout Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Drugs for the Treatment of Refractory Gout Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Drugs for the Treatment of Refractory Gout Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Drugs for the Treatment of Refractory Gout Sales Value (2021-2032) & (US$ Million) Figure 33. North America Drugs for the Treatment of Refractory Gout Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Drugs for the Treatment of Refractory Gout Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Drugs for the Treatment of Refractory Gout Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Drugs for the Treatment of Refractory Gout Sales Value (2021-2032) & (US$ Million) Figure 39. South America Drugs for the Treatment of Refractory Gout Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Drugs for the Treatment of Refractory Gout Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Drugs for the Treatment of Refractory Gout Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Tumor Necrosis Factor Inhibitors
  • PEGylated Recombinant Uricase
  • Interleukin Inhibitors
  • Other
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Zhuhai Livzon Biotechnology
  • Sobi
  • Qilu Pharmaceutical
  • Roche
  • Bio-Thera Solutions
  • Sandoz
  • Pfizer
  • Novartis
  • Kiniksa Pharmaceuticals
  • Horizo​​n Therapeutics
  • Hanwha Chemical
  • Fresenius Kabi
  • Biogen
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Drugs for the Treatment of Refractory Gout Sales Value (2021-2032)
  4. 1.2.2 Global Drugs for the Treatment of Refractory Gout Sales Volume (2021-2032)
  5. 1.2.3 Global Drugs for the Treatment of Refractory Gout Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Drugs for the Treatment of Refractory Gout Market Dynamics
  1. 2.1 Drugs for the Treatment of Refractory Gout Industry Trends
  2. 2.2 Drugs for the Treatment of Refractory Gout Industry Drivers
  3. 2.3 Drugs for the Treatment of Refractory Gout Industry Opportunities and Challenges
  4. 2.4 Drugs for the Treatment of Refractory Gout Industry Restraints
3 Drugs for the Treatment of Refractory Gout Market by Company
  1. 3.1 Global Drugs for the Treatment of Refractory Gout Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for the Treatment of Refractory Gout Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for the Treatment of Refractory Gout Sales Volume by Company (2021-2026)
  4. 3.4 Global Drugs for the Treatment of Refractory Gout Average Price by Company (2021-2026)
  5. 3.5 Global Drugs for the Treatment of Refractory Gout Company Ranking (2024-2026)
  6. 3.6 Global Drugs for the Treatment of Refractory Gout Company Manufacturing Base and Headquarters
  7. 3.7 Global Drugs for the Treatment of Refractory Gout Company Product Type and Application
  8. 3.8 Global Drugs for the Treatment of Refractory Gout Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Drugs for the Treatment of Refractory Gout Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Drugs for the Treatment of Refractory Gout Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Drugs for the Treatment of Refractory Gout Market by Type
  1. 4.1 Drugs for the Treatment of Refractory Gout Type Introduction
  2. 4.1.1 Tumor Necrosis Factor Inhibitors
  3. 4.1.2 PEGylated Recombinant Uricase
  4. 4.1.3 Interleukin Inhibitors
  5. 4.1.4 Other
  6. 4.2 Global Drugs for the Treatment of Refractory Gout Sales Volume by Type
  7. 4.2.1 Global Drugs for the Treatment of Refractory Gout Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Drugs for the Treatment of Refractory Gout Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Drugs for the Treatment of Refractory Gout Sales Value by Type
  11. 4.3.1 Global Drugs for the Treatment of Refractory Gout Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Drugs for the Treatment of Refractory Gout Sales Value by Type (2021-2032)
  13. 4.3.3 Global Drugs for the Treatment of Refractory Gout Sales Value Share by Type (2021-2032)
5 Drugs for the Treatment of Refractory Gout Market by Application
  1. 5.1 Drugs for the Treatment of Refractory Gout Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Drugs for the Treatment of Refractory Gout Sales Volume by Application
  6. 5.2.1 Global Drugs for the Treatment of Refractory Gout Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for the Treatment of Refractory Gout Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Drugs for the Treatment of Refractory Gout Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Drugs for the Treatment of Refractory Gout Sales Value by Application
  10. 5.3.1 Global Drugs for the Treatment of Refractory Gout Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Drugs for the Treatment of Refractory Gout Sales Value by Application (2021-2032)
  12. 5.3.3 Global Drugs for the Treatment of Refractory Gout Sales Value Share by Application (2021-2032)
6 Drugs for the Treatment of Refractory Gout Regional Sales and Value Analysis
  1. 6.1 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for the Treatment of Refractory Gout Sales by Region (2021-2032)
  3. 6.2.1 Global Drugs for the Treatment of Refractory Gout Sales by Region: 2021-2026
  4. 6.2.2 Global Drugs for the Treatment of Refractory Gout Sales by Region (2027-2032)
  5. 6.3 Global Drugs for the Treatment of Refractory Gout Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Drugs for the Treatment of Refractory Gout Sales Value by Region (2021-2032)
  7. 6.4.1 Global Drugs for the Treatment of Refractory Gout Sales Value by Region: 2021-2026
  8. 6.4.2 Global Drugs for the Treatment of Refractory Gout Sales Value by Region (2027-2032)
  9. 6.5 Global Drugs for the Treatment of Refractory Gout Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Drugs for the Treatment of Refractory Gout Sales Value (2021-2032)
  12. 6.6.2 North America Drugs for the Treatment of Refractory Gout Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Drugs for the Treatment of Refractory Gout Sales Value (2021-2032)
  15. 6.7.2 Europe Drugs for the Treatment of Refractory Gout Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Drugs for the Treatment of Refractory Gout Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Drugs for the Treatment of Refractory Gout Sales Value (2021-2032)
  21. 6.9.2 South America Drugs for the Treatment of Refractory Gout Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Drugs for the Treatment of Refractory Gout Sales Value Share by Country, 2025 VS 2032
7 Drugs for the Treatment of Refractory Gout Country-level Sales and Value Analysis
  1. 7.1 Global Drugs for the Treatment of Refractory Gout Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for the Treatment of Refractory Gout Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Drugs for the Treatment of Refractory Gout Sales by Country (2021-2032)
  4. 7.3.1 Global Drugs for the Treatment of Refractory Gout Sales by Country (2021-2026)
  5. 7.3.2 Global Drugs for the Treatment of Refractory Gout Sales by Country (2027-2032)
  6. 7.4 Global Drugs for the Treatment of Refractory Gout Sales Value by Country (2021-2032)
  7. 7.4.1 Global Drugs for the Treatment of Refractory Gout Sales Value by Country (2021-2026)
  8. 7.4.2 Global Drugs for the Treatment of Refractory Gout Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Drugs for the Treatment of Refractory Gout Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Drugs for the Treatment of Refractory Gout Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Drugs for the Treatment of Refractory Gout Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhuhai Livzon Biotechnology
  2. 8.1.1 Zhuhai Livzon Biotechnology Company Information
  3. 8.1.2 Zhuhai Livzon Biotechnology Business Overview
  4. 8.1.3 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhuhai Livzon Biotechnology Drugs for the Treatment of Refractory Gout Product Portfolio
  6. 8.1.5 Zhuhai Livzon Biotechnology Recent Developments
  7. 8.2 Sobi
  8. 8.2.1 Sobi Company Information
  9. 8.2.2 Sobi Business Overview
  10. 8.2.3 Sobi Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sobi Drugs for the Treatment of Refractory Gout Product Portfolio
  12. 8.2.5 Sobi Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Drugs for the Treatment of Refractory Gout Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Roche
  20. 8.4.1 Roche Company Information
  21. 8.4.2 Roche Business Overview
  22. 8.4.3 Roche Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Roche Drugs for the Treatment of Refractory Gout Product Portfolio
  24. 8.4.5 Roche Recent Developments
  25. 8.5 Bio-Thera Solutions
  26. 8.5.1 Bio-Thera Solutions Company Information
  27. 8.5.2 Bio-Thera Solutions Business Overview
  28. 8.5.3 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bio-Thera Solutions Drugs for the Treatment of Refractory Gout Product Portfolio
  30. 8.5.5 Bio-Thera Solutions Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz Drugs for the Treatment of Refractory Gout Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Drugs for the Treatment of Refractory Gout Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Novartis
  44. 8.8.1 Novartis Company Information
  45. 8.8.2 Novartis Business Overview
  46. 8.8.3 Novartis Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Novartis Drugs for the Treatment of Refractory Gout Product Portfolio
  48. 8.8.5 Novartis Recent Developments
  49. 8.9 Kiniksa Pharmaceuticals
  50. 8.9.1 Kiniksa Pharmaceuticals Company Information
  51. 8.9.2 Kiniksa Pharmaceuticals Business Overview
  52. 8.9.3 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Kiniksa Pharmaceuticals Drugs for the Treatment of Refractory Gout Product Portfolio
  54. 8.9.5 Kiniksa Pharmaceuticals Recent Developments
  55. 8.10 Horizo​​n Therapeutics
  56. 8.10.1 Horizo​​n Therapeutics Company Information
  57. 8.10.2 Horizo​​n Therapeutics Business Overview
  58. 8.10.3 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Horizo​​n Therapeutics Drugs for the Treatment of Refractory Gout Product Portfolio
  60. 8.10.5 Horizo​​n Therapeutics Recent Developments
  61. 8.11 Hanwha Chemical
  62. 8.11.1 Hanwha Chemical Company Information
  63. 8.11.2 Hanwha Chemical Business Overview
  64. 8.11.3 Hanwha Chemical Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hanwha Chemical Drugs for the Treatment of Refractory Gout Product Portfolio
  66. 8.11.5 Hanwha Chemical Recent Developments
  67. 8.12 Fresenius Kabi
  68. 8.12.1 Fresenius Kabi Company Information
  69. 8.12.2 Fresenius Kabi Business Overview
  70. 8.12.3 Fresenius Kabi Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Fresenius Kabi Drugs for the Treatment of Refractory Gout Product Portfolio
  72. 8.12.5 Fresenius Kabi Recent Developments
  73. 8.13 Biogen
  74. 8.13.1 Biogen Company Information
  75. 8.13.2 Biogen Business Overview
  76. 8.13.3 Biogen Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Biogen Drugs for the Treatment of Refractory Gout Product Portfolio
  78. 8.13.5 Biogen Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Drugs for the Treatment of Refractory Gout Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Drugs for the Treatment of Refractory Gout Product Portfolio
  84. 8.14.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Drugs for the Treatment of Refractory Gout Value Chain Analysis
  2. 9.1.1 Drugs for the Treatment of Refractory Gout Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Drugs for the Treatment of Refractory Gout Sales Mode & Process
  6. 9.2 Drugs for the Treatment of Refractory Gout Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Drugs for the Treatment of Refractory Gout Distributors
  9. 9.2.3 Drugs for the Treatment of Refractory Gout Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst